Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
第2相
完了
NCT03472586
| 対象疾患 | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 14 名 |
|---|
| 介入（薬剤） | Ipilimumab, Nivolumab, Embolization Therapy |
|---|
| 開始日 | 2018年5月2日 |
|---|
| 完了日 | 2022年12月31日 |
|---|
| 結果公開日 | 2023年11月29日 |
|---|
概要
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. · Participants
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 8 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 5 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 1 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。